1. Ouyang, W., Li, Q., Niu, Q., Qui, M., Fu, H., Du, Y., and Mo, X. (2023). A multiplexed time-resolved fluorescence resonance energy transfer ultrahigh-throughput screening assay for targeting SMAD4-SMAD3-DNA complex. J Mol Cell Biol. 2023 Nov 15:mjad068. doi: 10.1093/jmcb/mjad068. PDF link
2. Mo, X., Niu, Q., Ivanov, A.A., Tsang, Y.H., Tang, C., Shu, C., Li, Q., Qian, K., Wahafu, A., Doyle, S.P., et al. Systematic discovery of mutation-directed neo-protein-protein interactions in cancer. Cell. 2022. S0092-8674(22)00461-5. doi: 10.1016/j.cell.2022.04.014. PDF link
3. Hahn WC, et al. and the Cancer Target Discovery and Development Network. An expanded universe of cancer targets. Cell. 2021. 184(5):1142-1155. PDF link
4. Tang C, Mo X, Niu Q, Wahafu A, Yang X, Qui, M, Ivanov AA, Du Y, Fu H. Hypomorph mutation-directed small molecule protein-protein interaction inducers to restore mutant SMAD4-suppressed TGFb signaling. Cell Chem Biol. 2021. 28(5):636-647. PDF link
5. Mo X, Tang C, Niu Q, Ma T, Du Y, Fu H. HTiP: High-Throughput Immunomodulator Phenotypic Screening Platform to Reveal IAP Antagonists as Anti-cancer Immune Enhancers. Cell Chem Biol. 2018. pii: S2451-9456(18)30433-1. PDF link